Full Text View
Tabular View
No Study Results Posted
Related Studies
Assessment of GVG for the Treatment of Methamphetamine Dependence
This study has been completed.
Study NCT00506935   Information provided by National Institute on Drug Abuse (NIDA)

First Received on July 24, 2007.   Last Updated on August 6, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Methamphetamine Addiction
Additional conditions recognized in this trial
Behavior, Addictive
More general conditions related to this trial
Compulsive Behavior
Impulsive Behavior
Interventions listed in this trial
GVG
placebo
Additional drug interventions recognized in this trial
Amphetamine
Methamphetamine
Vigabatrin
More general drug interventions related to this trial
Adrenergic Agents
Adrenergic Uptake Inhibitors
Anticonvulsants
Autonomic Agents
Central Nervous System Agents
Central Nervous System Stimulants
Dopamine Agents
Dopamine Uptake Inhibitors
Enzyme Inhibitors
GABA Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sympathomimetics
Therapeutic Uses
Sponsors listed in this trial
National Institute on Drug Abuse (NIDA)
University of California, Los Angeles


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services